Goto
Top of Page Study Description Study Design
Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Heart Diseases | Procedure: Open heart surgery to address the heart disease Device: Close the defects with XenoSure Patch Device: Close the defects with Chest Polyester Patch | Not Applicable |
The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.
There will be 144 subjects enrolled, including 72 subjects in the trial arm and 72 subjects in the control arm.
Goto
Top of Page Study Description Study Design
Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
| Study Type : | Interventional (Clinical Trial) |
| EstimatedEnrollment : | 144 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Random, Controlled, Single-blinded, Multi-center and Non-inferiority Clinical Study to Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair |
| Actual Study Start Date : | August 15, 2017 |
| Estimated Primary Completion Date : | November 15, 2025 |
| Estimated Study Completion Date : | February 15, 2026 |
Resource links provided by the National Library of Medicine 
MedlinePlus related topics: HeartDiseases
U.S. FDA Resources
Goto
Top of Page Study Description Study Design
Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
| Arm | Intervention/treatment |
|---|---|
| Experimental: Test Arm In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch | Procedure: Open heart surgery to address the heart disease The patient will first have open heart surgery to achieve access to the diseased site in the heart Device: Close the defects with XenoSure Patch The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch. |
| Active Comparator: Control Arm In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch | Procedure: Open heart surgery to address the heart disease The patient will first have open heart surgery to achieve access to the diseased site in the heart Device: Close the defects with Chest Polyester Patch The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co. |
Goto
Top of Page Study Description Study Design
Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Primary Outcome Measures :
- Leakage rate at 6 month post-procedure measured by ultrasound [TimeFrame:6 months]
The heart defects should be totally closed by the patch. Any residual flow or leakage, measured by ultrasound, will be recorded. The percentage of the patients that show leakage post-procedure is the failure rate. The study is considered achieved its primary endpoint if the failure rate of the test device is non-inferior to the rate of the comparator device.
Goto
Top of Page Study Description Study Design
Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 6 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Man or woman aged below 6 years old
- The expected lifetime of no less than 12 months
- Patients with congenital heart disease in symptoms of ventricular septal defect, atrial septal defect and tetralogy of fallot who need the surgical repair.
- Physical conditions and vital signs meet requirements for the surgery.
- The subjects and/or their guardians sign the written Informed Consent Form.
Exclusion Criteria:
- Patients with severe visceral diseases in liver, kidney, etc.
- Patients have unstable vital signs and not suitable for the indications.
- Patients with severe allergic history (especially allergic to bovine materials)
- Patients with the past medical history of severe immunodeficiency disease
- The subject has used or plans to use immunomodulatory drugs for more than half a year.
- The subject with poor blood clotting function, which is defined as that pre-operative INR or APTT is prolonged over 30% than the reference value without drug intervention, or that blood platelet count is less than 100*10^9/L.
- The subject has severe kidney disorders or diseases with the estimated glomerular filtration rate [GRF]<30mL/min/1.73m2.
- The subject's ALT or AST level is 2.5 times higher than the upper normal limit or the subject has active liver disease or icterus.
- The subject has participated in another clinical study within past 3 months or is participating in another clinical study now.
- The investigator believes that the subject has other reasons unsuitable for inclusion.
Goto
Top of Page Study Description Study Design
Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03176225
Contacts
| Contact: Vic Zhang | 781-425-1729 | xzhang@lemaitre.com |
Locations
| China, Beijing | |
| Chinese PLA General Hospital | Recruiting |
| Beijing, Beijing, China, 100853 | |
| Contact: Vic Zhang 7814251729 xzhang@lemaitre.com | |
Sponsors and Collaborators
LeMaitre Vascular
Goto
Top of Page Study Description Study Design
Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
| Responsible Party: | LeMaitre Vascular |
| ClinicalTrials.gov Identifier: | NCT03176225 |
| Other Study ID Numbers: | P15077-1 |
| First Posted: | June 5, 2017 Key Record Dates |
| Last Update Posted: | March 10, 2023 |
| Last Verified: | March 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | Yes |
Additional relevant MeSH terms:
| Heart Diseases Cardiovascular Diseases |
To Top
